- Aetna coverage for Zepbound varies by plan — employer-sponsored, marketplace, and Medicare Advantage plans each differ
- Most Aetna plans require prior authorization including documented BMI and comorbidities
- The FDA’s sleep apnea indication for Zepbound may open an additional coverage pathway
- PEAK’s insurance team verifies your benefits and handles prior authorization before your first visit
Note: PEAK accepts Aetna commercial plans. We do not accept Aetna Medicare Advantage plans.
The short answer
Some Aetna plans cover Zepbound (tirzepatide) for weight loss, but many do not. Coverage depends entirely on your specific plan — the type of plan you have, who your employer is, and whether weight loss medications are included in your formulary.
There is no single “Aetna policy” on Zepbound. Aetna administers hundreds of different plan designs, each with its own formulary, exclusion list, and prior authorization requirements. Two people with Aetna cards can have completely different coverage.
Zepbound (tirzepatide) was FDA-approved for chronic weight management in November 2023. It is the same active ingredient as Mounjaro, but approved under a different brand name specifically for weight loss. Insurance plans treat these as separate medications with separate coverage rules.
Plans that may cover Zepbound
Aetna plan types that are more likely to include Zepbound coverage:
- Large employer-sponsored plans — These are the most common source of Zepbound coverage. Employers choose whether to include anti-obesity medications in their formulary. Some large employers have added Zepbound; many have not.
- Self-funded employer plans administered by Aetna — The employer, not Aetna, makes the formulary decisions. Coverage is entirely up to the employer’s benefits team.
- Aetna Medicare Advantage plans — Some Medicare Advantage plans have started covering GLP-1 medications for weight loss, though this is still uncommon.
- ACA marketplace plans — Coverage varies by state and plan tier. Anti-obesity medications are not required to be covered under the ACA essential health benefits.
Aetna individual plans, short-term plans, and plans with explicit “weight loss medication exclusions” typically do not cover Zepbound. If your plan documents include a weight loss plan exclusion, Zepbound will generally be denied regardless of medical necessity.
Prior authorization requirements
Even when Aetna covers Zepbound, you will almost certainly need prior authorization (PA). This is a process where your prescribing clinician submits documentation to Aetna proving that the medication is medically necessary for you.
Aetna’s typical PA requirements for Zepbound include:
- Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
- Evidence of participation in a structured weight management program (diet, exercise, behavioral counseling) for a minimum period — often 3 to 6 months
- Documentation that other weight loss interventions have been attempted
- Prescriber must be a physician, NP, or PA with appropriate prescribing authority
Prior authorization is not a denial — it is a documentation requirement. The better the documentation, the higher the approval rate.
At PEAK, our clinical team documents everything from your first visit with PA requirements in mind. We know what Aetna looks for because we submit these requests routinely.
The sleep apnea indication
In late 2024, the FDA approved Zepbound for a second indication: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This is significant for insurance coverage because it creates a separate clinical pathway.
If you have a documented sleep apnea diagnosis — confirmed by a sleep study — your clinician may be able to submit the prior authorization under the OSA indication rather than (or in addition to) the weight management indication. Some Aetna plans that exclude weight loss medications may still cover medications prescribed for sleep apnea.
The sleep apnea pathway is not a workaround — it is a legitimate FDA-approved indication. Your clinician must document a genuine OSA diagnosis. At PEAK, we evaluate every patient individually, and if OSA is present, we use the most appropriate clinical pathway for both treatment and coverage.
What you’ll pay
Even with Aetna coverage, your out-of-pocket cost depends on your plan’s cost-sharing structure. Here is a general breakdown of what patients typically see:
| Coverage scenario | Estimated monthly cost |
|---|---|
| Preferred formulary tier with PA approved | Plan-based copay |
| Non-preferred tier with PA approved | Plan-based copay |
| Covered after deductible | Full cost until deductible met, then copay |
| Not covered / weight loss exclusion | Cash price varies by pharmacy |
These figures are estimates and vary significantly by plan. Your actual cost depends on your deductible status, coinsurance percentage, and whether you have reached your out-of-pocket maximum.
Eli Lilly, the manufacturer of Zepbound, offers a savings card program for eligible commercially insured patients. If your insurance covers Zepbound, the savings card may reduce your copay further. PEAK’s team can help you determine whether you qualify.
How to check your coverage
The most reliable way to confirm your Aetna coverage for Zepbound is to follow these steps:
- Check your formulary. Log in to your Aetna member portal and search for “tirzepatide” or “Zepbound” in the formulary lookup tool. If it does not appear, it may not be covered.
- Review your plan documents. Look for a “weight loss medication exclusion” or “anti-obesity medication” section. If your plan explicitly excludes these, coverage is unlikely regardless of medical necessity.
- Call the number on your card. Ask specifically: “Is tirzepatide (Zepbound) covered under my plan for chronic weight management?” and “What are the prior authorization requirements?”
- Ask PEAK to verify for you. Our insurance team does this daily. We can check your benefits, confirm formulary status, and identify the fastest path to approval.
What if you’re denied?
A denial is not the end of the road. If Aetna denies your prior authorization for Zepbound, there are several next steps:
- Peer-to-peer review. Your prescribing clinician can request a phone call with Aetna’s medical director to present your case directly. This often overturns initial denials when documentation is strong.
- Formal appeal. You have the right to appeal any PA denial. Aetna must review your appeal within specific timeframes (typically 30 days for standard appeals, 72 hours for expedited).
- Alternative pathway. If the weight management indication is denied, your clinician may explore the sleep apnea indication or other clinically appropriate pathways.
- Step therapy completion. Some Aetna plans require you to try other medications first. If you complete the required step therapy and document the results, Zepbound may be approved on a subsequent request.
How we help at PEAK
Insurance navigation is one of the most common barriers to starting treatment. At PEAK, we handle it before you walk through the door.
Here is what our process looks like:
- Benefits verification. We check your Aetna plan for Zepbound coverage, formulary status, and any exclusions — before your first appointment.
- Prior authorization. Our clinical team prepares and submits your PA with the documentation Aetna requires. We know their criteria because we work with them regularly.
- Denial management. If your PA is denied, we manage the appeal process, including peer-to-peer reviews and formal appeals.
- Alternative pathways. If Zepbound is not covered, we evaluate other FDA-approved options that may be on your formulary — including Wegovy, Saxenda, or Contrave.
We tell you what your insurance covers before you commit to anything. If your plan does not cover the medication you need, we will tell you that directly — along with what your options are.
Important safety information: Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
